PerkinElmer Completes Acquisition of ViaCell
ViaCell's ViaCord(R) product offering allows expectant families to preserve their baby's umbilical cord blood at the time of birth for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. The addition of ViaCord and ViaCell's highly qualified sales and marketing organization provides PerkinElmer with a leading offering in the rapidly growing cord blood banking business, as well as an enhanced ability to reach obstetric professionals and prospective parents. ViaCell customers will continue to benefit from ViaCord's high-quality cord blood banking offering and expertise, and now will have access to a wider range of neonatal, prenatal and maternal health solutions from PerkinElmer.
"PerkinElmer is committed to protecting the health of mothers and babies from pregnancy through birth and beyond," said Robert F. Friel, President and Chief Operating Officer, PerkinElmer. "The addition of ViaCell marks another step in our efforts to become a leading provider of innovative prenatal, neonatal and maternal healthcare solutions. We will continue to look for opportunities to build our product portfolio and provide the most comprehensive and accurate assessment of newborn and maternal health to families and their healthcare providers."
PerkinElmer is the world's leading provider of newborn screening systems, offering the world's first and only tandem mass spectrometry (MS/MS) kit cleared by the FDA as an aid to screening for inborn errors of metabolism. The Company continues to drive the advancement of newborn screening with the capability to analyze more than 40 disease markers with a single blood sample. PerkinElmer estimates that every baby screened in the U.S. today is tested using its screening tools, and has helped identify more than 100,000 infants globally who were determined to be at risk for potentially life-threatening diseases.
As part of its rapidly growing offerings for prenatal and maternal health, PerkinElmer currently offers Ultra-Screen(R), a first-trimester prenatal screening protocol designed to provide patient-specific risk assessment for certain chromosomal abnormalities, through its clinical test subsidiary, NTD Laboratories. The Company also holds a global licensing agreement to develop assay kits for the ADAM12 biochemical marker, which has broad potential in maternal health screening for fetal chromosomal abnormalities, and has secured global rights for Placental Protein 13 (PP13), a new maternal serum marker currently under investigation that has shown potential for early detection of pre-eclampsia in low-risk groups.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to our genetic screening business. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
Michael A. Lawless, 781-663-5659
Kevin J. Lorenc, 781-663-5701
Posted: November 2007